Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 88, Issue 8, Pages 647-651Publisher
WILEY
DOI: 10.1002/ajh.23466
Keywords
-
Categories
Funding
- National Institutes of Health [1 R03 CA 101496-01]
- European Community [200950]
- Nordic Cancer Union
- Swedish Cancer Society
- Swedish Research Council
- Lion's Cancer Research Foundation in Uppsala
- Lion's Cancer Research Foundation in Umea
Ask authors/readers for more resources
Most previous studies on telomere length (TL) in chronic lymphocytic leukemia (CLL) are based on referral cohorts including a high proportion of aggressive cases. Here, the impact of TL was analyzed in a population-based cohort of newly diagnosed CLL (n=265) and in relation to other prognostic markers. Short telomeres were particularly associated with high-risk genetic markers, such as NOTCH1, SF3B1, or TP53 aberrations, and predicted a short time to treatment (TTT) and overall survival (OS) (both P<0.0001). TL was an independent prognostic factor and subdivided patients with otherwise good-prognostic features (e.g., mutated IGHV genes, favorable cytogenetics) into subgroups with different outcome. Furthermore, in follow-up samples (n=119) taken 5-8 years after diagnosis, TL correlated well with TL at diagnosis and remained unaffected by treatment. Altogether, these novel data indicate that short TL already at diagnosis is associated with poor outcome in CLL and that TL can be measured at later stages of the disease. Am. J. Hematol. 88:647-651, 2013. (c) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available